Wednesday, July 8, 2026

Patent intelligence · US

US 10564149

Populations of mesenchymal stem cells that secrete neurotrophic factors

granted A61KA61K35/28A61PA61P21/02
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 14
Applicant portfolio 8
Patent details — US 10564149

Quick answer

US 10564149 (Populations of mesenchymal stem cells that secrete neurotrophic factors) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Feb 18, 2020. Expires Feb 13, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
5
CPC classes
A61K, A61K35/28, A61P, A61P21/02, A61P29/00, A61P37/00

More from BRAINSTORM CELL THERAPEUTICS LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12233092

    MSC-NTF specific exosomes and use thereof

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Feb 20, 2045

    granted
  2. US 11185572

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Nov 25, 2041

    granted
  3. US 10052363

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Aug 16, 2038

    granted
  4. US 10046010

    Methods of generating mesenchymal stem cells which secrete neurotrophic factors

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Aug 9, 2038

    granted
  5. US 9474787

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Oct 20, 2036

    granted
  6. US 8900574

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Nov 27, 2034

    granted
  7. US 8663987

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Feb 27, 2034

    granted

Frequently asked questions

What is US patent 10564149?

US 10564149 (Populations of mesenchymal stem cells that secrete neurotrophic factors) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Feb 18, 2020. Expires Feb 13, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10564149?

BRAINSTORM CELL THERAPEUTICS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does US 10564149 expire?

Our index shows an expiration date of Feb 13, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.